On the other hand, Głowacka et al. (2021) analyzed the utilization of angiotensin-converting enzyme inhibitors (ACE-is) and Angiotensin Receptor Blockers (ARBs) in the context of the risk of AKI among patients diagnosed with COVID-19 [6]. The gene discussed is ACE; the disease is COVID-19.